LncRNA enhances the chemosensitivity of non-small cell lung cancer cells to Gemcitabine via miR-17-5p/p21 axis.

Background: This study investigated the inhibitory effects of lncRNA HLA Complex Group 11 () on non-small cell lung cancer (NSCLC) and the molecular mechanisms.

Research Design And Methods: Bioinformatics analysis was conducted to determine the downstream targeted gene miR-17-5p/p21 and predict their binding sites. qRT-PCR and Western blot were used to detect expression levels, and dual luciferase and RIP assays were adopted to verify binding relationship.

Results: The lncRNA /miR-17-5p/p21 axis was found to regulate drug resistance, proliferation, apoptosis, and cell cycle of A549 and A549-Gemcitabine (GEM) cells. acted as a ceRNA binding to miR-17-5p, which repressed p21 expression in turn. In vivo experiments demonstrated that HCG11 hindered tumor growth. Therefore, lncRNA , by targeting the miR-17-5p/p21 axis, suppressed GEM resistance and malignant progression of NSCLC cells.

Conclusions: This study provides a reference for investigating the potential value of lncRNA in the diagnosis of NSCLC and finding potential targets against clinical chemotherapeutic resistance in NSCLC.